|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
4,150,000 |
Market
Cap: |
537.01(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.1294 - $0.38 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aptevo Therapeutics is a clinical-stage, research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. Co.'s lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using Co.'s ADAPTIR modular protein technology platform. Co.'s preclinical candidate APVO442 was developed using its ADAPTIR-FLEX modular protein technology platform. The ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of improving the human immune system against cancer cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gross Jane A |
See Remarks |
|
2017-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,093 |
78,509 |
|
- |
|
White Marvin L |
President and CEO |
|
2017-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
53,471 |
66,332 |
|
- |
|
Gross Jane A |
See Remarks |
|
2017-03-10 |
4 |
D |
$1.78 |
$6,830 |
D/D |
(3,837) |
40,416 |
|
- |
|
Gross Jane A |
See Remarks |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,506 |
44,253 |
|
- |
|
Stromatt Scott C |
Chief Medical Officer and SVP |
|
2017-03-10 |
4 |
D |
$1.78 |
$11,695 |
D/D |
(6,570) |
69,072 |
|
- |
|
Stromatt Scott C |
Chief Medical Officer and SVP |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,836 |
75,642 |
|
- |
|
Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
|
2017-03-10 |
4 |
D |
$1.78 |
$12,060 |
D/D |
(6,775) |
41,284 |
|
- |
|
Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
|
2017-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,863 |
46,274 |
|
- |
|
Gross Jane A |
See Remarks |
|
2017-03-09 |
4 |
D |
$1.80 |
$4,631 |
D/D |
(2,573) |
29,747 |
|
- |
|
Gross Jane A |
See Remarks |
|
2017-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,727 |
32,320 |
|
- |
|
Stromatt Scott C |
Chief Medical Officer and SVP |
|
2017-03-09 |
4 |
D |
$1.80 |
$6,620 |
D/D |
(3,678) |
50,806 |
|
- |
|
Stromatt Scott C |
Chief Medical Officer and SVP |
|
2017-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,902 |
54,484 |
|
- |
|
Gross Jane A |
See Remarks |
|
2017-03-01 |
4 |
D |
$2.02 |
$4,339 |
D/D |
(2,148) |
22,593 |
|
- |
|
Gross Jane A |
See Remarks |
|
2017-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,140 |
25,011 |
|
- |
|
Stromatt Scott C |
Chief Medical Officer and SVP |
|
2017-03-01 |
4 |
D |
$2.02 |
$10,730 |
D/D |
(5,312) |
40,582 |
|
- |
|
Stromatt Scott C |
Chief Medical Officer and SVP |
|
2017-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,269 |
45,894 |
|
- |
|
Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
|
2017-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,066 |
29,196 |
|
- |
|
Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
|
2017-03-01 |
4 |
D |
$2.02 |
$3,911 |
D/D |
(1,936) |
22,450 |
|
- |
|
Stromatt Scott C |
Chief Medical Officer and SVP |
|
2017-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,381 |
29,625 |
|
- |
|
Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
|
2017-02-03 |
4 |
D |
$1.92 |
$15,886 |
D/D |
(8,274) |
17,066 |
|
- |
|
Lamothe Jeffrey G. |
SVP, CFO and Treasurer |
|
2017-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,340 |
25,340 |
|
- |
|
Gross Jane A |
See Remarks |
|
2017-02-03 |
4 |
D |
$1.92 |
$11,370 |
D/D |
(5,922) |
15,871 |
|
- |
|
Gross Jane A |
See Remarks |
|
2017-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,135 |
21,793 |
|
- |
|
Emergent Biosolutions Inc. |
10% Owner |
|
2016-08-01 |
4/A |
D |
$0.00 |
$0 |
D/D |
(20,229,849) |
0 |
|
- |
|
Emergent Biosolutions Inc. |
10% Owner |
|
2016-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(20,230,074) |
0 |
|
- |
|
128 Records found
|
|
Page 5 of 6 |
|
|